Retatrutide is not yet FDA approved, unlike many GLP-1 agonists, retatrutide will most likely be a weekly injection, delivered subcutaneously into the arm, thigh or stomach area in a self-inject pen
Eur J Heart Fail 22:14951503 Seferovi PM, Fragasso G, Petrie M, Mullens W, Ferrari R, Thum T, Bauersachs J, Anker SD, Ray R, avuolu Y, Polovina M, Metra M, Ambrosio G, Prasad K, Seferovi J, Jhund PS, Dattilo G, elutkiene J, Piepoli M, Moura B, Chioncel O, Ben Gal T, Heymans S, Jaarsma T, Hill L, Lopatin Y, Lyon AR, Ponikowski P, Lainak M, Jankowska E, Mueller C, Cosentino F, Lund LH, Filippatos GS, Ruschitzka F, Coats AJS, Rosano GMC (2020) Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure
Thats because many drugs promoted weight loss of only about 5%, the lower limit of what will make a difference in someones health
Medi-Cal Rx has announced exclusion effective Jan 1, 2026